Developer docs
API playgroundTry for free, no card

Search company profiles

OEP Pharma

Full company profile

uuid002k1kk

Namestring
OEP Pharma
Legal namestring
OEP Pharma
Websiteurl
oeppharma.com
Company typeenum
Public
Founded yearint
1982
Descriptiontext

OEP Pharma is the US commercial identity of OEP Group, a publicly traded (TWSE), founder-led pharmaceutical company founded in 1982 in Taiwan by Peter Tsai. The company operates as a vertically integrated pharmaceutical platform with ~1,000 employees across 10 countries, combining (1) Asian licensing and distribution of branded pharmaceuticals via a 350+ person sales force in 7 countries (Taiwan, Hong Kong, Singapore, Malaysia, Vietnam, Indonesia, Myanmar), (2) ANDA generic products commercialized in the US through distribution partners such as PAI (e.g., Vancomycin hydrochloride capsules), (3) co-development of 505(b)(2) specialty products with partners including DURECT (Methydur / ORADUR-Methylphenidate ER) and in-licensing of late-stage assets from partners including CEL-SCI (Multikine cancer immunotherapy, 9 countries) and Supernus (Trokendi XR migraine, 7 Asian countries), and (4) CMO/CDMO and CRO/clinical-trial-operations services. Revenue is generated through licensing royalties and distribution margins on Asian branded sales, transaction-based US generic sales via channel partners, development fees and milestones from 505(b)(2) co-development, and managed-service CMO/CDMO/CRO contracts for global pharma customers.

The technical backbone is two PIC/S GMP, EU GMP, US FDA (oral-dosage) and Taiwan FDA-certified manufacturing facilities in Yunlin, Taiwan, totaling roughly 286,000 square feet (162,532 sq ft oral-dosage with 16 production suites, 30 cleanrooms, and 4 packaging lines; 123,318 sq ft injectables with fully integrated isolator for sterile fill-finish through lyophilization). Capability depth centers on complex modified-release oral solids — Multi-Phasic Release Technology (MPRT), Multi-Day Transdermal Drug Delivery (MTDD), Zero Order Release osmotic and pellet systems (OROS and PROS), and Nanoparticle Micellar Delivery — plus specialty injectables in liposomes, emulsions, suspensions, microspheres, and nanoparticles. TAA-compliance (Taiwan being a TAA-compliant country) permits direct US government sales.

The customer base is enterprise pharma: long-term Asian distribution partners (Pierre Fabre, Sanofi-Rhône-Poulenc, Chiesi, UCB, Elan/Perrigo, Teva, Kissei, Recordati) and Western co-development partners (DURECT, CEL-SCI, Supernus, Debiopharm, Plethora, Synthon, Summit Therapeutics, Tissuetech, Nanocarrier, Second Sight). The website discloses both market cap and revenue at $200MM. Strategic emphasis through 2019–2023 is North America (San Diego HQ established 2019, US FDA certification pursuit on the injectables plant) layered on top of the established Asian commercial franchise.

Short descriptiontext

OEP Pharma is the US arm of Taiwan-listed OEP Group, a full-service pharmaceutical company providing Asia-Pacific licensing and distribution, US ANDA generic commercialization, 505(b)(2) co-development, and CMO/CDMO/CRO services to global pharma partners. It operates from two PIC/S-, EU GMP-, and US FDA-certified manufacturing facilities in Yunlin, Taiwan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices12 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceutical manufacturing, contract pharmaceutical manufacturing, drug delivery technology, pharmaceutical licensing distribution, specialty pharma co-development
Industry5 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing & Distribution of Branded Pharma in Asia
TypeLicensing Royalties
Description

OEP serves as commercial partner for global pharmaceutical companies, distributing branded products through their extensive Asian sales networks. Revenue comes from licensing fees, distribution margins, and milestone payments.

oeppharma.com
2ANDA Products (Generic Pharmaceuticals)
TypeTransaction Fee
Description

Manufacturing and marketing generic pharmaceutical products in the US and select markets through commercial distributors. Revenue from product sales through distribution partners.

oeppharma.com
3Co-development of 505(b)(2)s
TypeProfessional Services
Description

Co-development of specialty pharmaceutical products with partners, providing financial resources, technology, and manufacturing capacity. Revenue from development fees, regulatory milestones, and product commercialization.

oeppharma.com
4CMO/CDMO/CRO Services
TypeManaged Services
Description

Contract manufacturing and development services for oral dosage and injectable products. Services include analytical method development, clinical trial management, quality control, and compendial testing.

oeppharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OEP Pharma is a full-service global pharmaceutical company that develops, manufactures, and distributes drug products across North America and Asia-Pacific. Its operations span ANDA generic manufacturing, 505(b)(2) specialty co-development, branded pharmaceutical licensing and distribution in Asia through 350+ person sales teams, and CMO/CDMO/CRO services executed from two FDA-certified, PIC/S GMP-compliant facilities in Yunlin, Taiwan.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

OEP Pharma is a full-service pharmaceutical company offering a unified platform spanning drug development, manufacturing, and commercial distribution. Its product portfolio consists of three core pillars: (1) a growing ANDA portfolio of generic pharmaceuticals (immediate-release and controlled-release products including Vancomycin, Carisoprodol, Miglitol, Glyburide, Pitavastatin, Ezetimibe, Rivastigmine), all manufactured in TAA-compliant Taiwan; (2) a 505(b)(2) pipeline of specialty pharma products co-developed with partners such as DURECT (ORADUR-Methylphenidate ER / Methydur for ADHD) and in-licensed from companies such as CEL-SCI (Multikine, cancer immunotherapy) and Supernus Pharmaceuticals (Trokendi XR, CNS/migraine); and (3) CMO/CDMO and CRO services including oral dosage manufacturing (complex modified-release), cytotoxic injectables manufacturing, analytical services, clinical trial operations, and commercialization across Asia. These capabilities are interconnected: OEP manufactures its own portfolio while also offering manufacturing as a service to partners, and leverages its sales networks to distribute both self-manufactured and in-licensed products across North America and Asia-Pacific.

Product and service13 records
1ANDA Generic Pharmaceutical Portfolio
CategoryGeneric Pharmaceuticals (ANDA)
Description

Out-licensed and distributed generic pharmaceuticals (ANDA products) for the US market via commercial distributors such as PAI, manufactured at OEP's FDA-certified facilities in Yunlin, Taiwan.

2505(b)(2) Specialty Pharmaceutical Pipeline
CategorySpecialty Pharmaceuticals (505(b)(2))
Description

Specialty pharmaceutical products developed via the 505(b)(2) regulatory pathway, co-developed with partners such as DURECT, with some marketed in Taiwan.

3Vancomycin Hydrochloride Capsules
CategoryGeneric Pharmaceuticals (ANDA)
Description

An antibiotic generic medication marketed in the U.S. via out-licensing partner PAI (Pharmaceutical Associates, Inc.), part of OEP's ANDA portfolio.

4ORADUR-Methylphenidate ER / Methydur
CategorySpecialty Pharmaceuticals (505(b)(2))
Description

A 505(b)(2) ADHD drug co-developed with DURECT using ORADUR technology; OEP holds development and commercialization rights in 14 Asian and South Pacific countries and it is approved and commercially launched in Taiwan.

5Multikine
CategoryIn-Licensed Biopharmaceutical
Description

CEL-SCI's lead investigational cancer immunotherapy drug, exclusively in-licensed by OEP for distribution in 9 countries.

6Trokendi XR
CategoryIn-Licensed Branded Pharmaceutical
Description

A CNS drug that helps prevent migraines, in-licensed from Supernus Pharmaceuticals and launched in 7 Asian countries.

7Branded Asia Pharmaceutical Portfolio
CategoryBranded Pharmaceuticals (Asia)
Description

Branded pharmaceutical products marketed across Asian markets including Zulitor, Trokendi, Pitator, Navelbine, Methydur, and others covering cardiovascular, neurology, diabetes, respiratory, and oncology treatments.

8Injectables Manufacturing (Cytotoxic Oncology)
CategoryContract Manufacturing (CMO)
Description

Contract manufacturing of cytotoxic injectable oncology products using fully integrated isolators for sterile production from filling to lyophilization, supporting liposomes, emulsions, suspensions, microspheres, and nanoparticles delivery platforms from a 123,318 square foot PIC/S GMP-certified facility in Yunlin, Taiwan.

9Oral Dosage Manufacturing
CategoryContract Manufacturing (CMO)
Description

Contract manufacturing of complex modified-release oral dosage forms from a 162,532 square foot PIC/S GMP, EU GMP, Taiwan and US FDA-certified facility in Yunlin, Taiwan, with 16 production suites, 30 cleanrooms, and 4 packaging lines.

10CMO/CDMO Services
CategoryContract Development and Manufacturing (CDMO)
Description

Integrated contract manufacturing and development services for oral dosage and injectable products, including analytical method development and validation, quality control, and compendial testing (USP, BP, EP, JP), from FDA-certified, PIC/S GMP facilities in Taiwan.

11CRO / Clinical Trial Operations Services
CategoryContract Research (CRO)
Description

Agile clinical trial research services including site selection, trial management, and delivery of high-quality clinical data in Asia (Taiwan, Singapore, Korea), Australia, and New Zealand.

12Licensing and Distribution Services (Branded Pharma in Asia)
CategoryLicensing and Distribution
Description

Commercial licensing and distribution of branded pharmaceutical products across Asia, leveraging nearly 40 years of local regulatory expertise and 350+ person sales teams in 7 countries.

13505(b)(2) Co-Development Services
CategorySpecialty Pharma Co-Development
Description

Co-development partnerships for 505(b)(2) specialty pharmaceutical products, providing financial resources, proprietary drug delivery technology, and manufacturing capacity to bring specialty pharmaceuticals to market.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2009-01-01
Description

In 2009, DURECT granted OEP the development and commercialization rights to ORADUR-Methylphenidate ER Capsule (Methydur Sustained Released Capsules), its lead ORADUR-ADHD program, in 14 Asian and South Pacific countries. Together, OEP and DURECT developed a lead formulation based on clinical trial research. OEP oversaw phase III clinical trials in Taiwan, handles manufacturing, and has received or is pursuing regulatory approvals in 14 countries including Australia and New Zealand.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

OEP's ANDA portfolio provides high-quality generic medications at affordable prices. With commercial partner PAI, they launched Vancomycin hydrochloride capsules, a commonly used antibiotic, into the US market. PAI distributes the product through their North American distribution network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CEL-SCI is a pioneer in cancer immunotherapy drugs. OEP has an exclusive licensing agreement for Multikine, CEL-SCI's lead investigational therapy. OEP invested in CEL-SCI, funded a portion of Multikine's nine-year Phase III clinical trial, and obtained licensing rights to distribute Multikine in nine countries. The global Phase 3 study has ended and is in the data analysis stage. It is believed to be the largest head and neck cancer clinical study ever conducted.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

OEP partnered with Supernus Pharmaceuticals to launch Trokendi XR, a CNS drug that helps prevent migraines, in 7 Asian countries. OEP leverages their local sales teams and regulatory expertise to commercialize the product in the region.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Pierre Fabre is a long-standing commercial partner of OEP for branded pharmaceutical distribution in Asia. OEP has been the commercial partner of choice for Pierre Fabre for nearly 40 years, helping them access Asian markets including Taiwan and ASEAN countries.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Sanofi's Rhône-Poulenc division was one of OEP's early major commercial distribution partners, establishing the company's reputation as the regional distributor of choice in the 1980s and 1990s.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Chiesi partnered with OEP for licensing of respiratory products in Asian markets. OEP secured licensing deals to expand Chiesi's respiratory product portfolio into the Asian region through their established sales networks.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

UCB partnered with OEP for licensing of their CNS portfolio in Asian markets. OEP led the expansion of sales into Asian markets for UCB's central nervous system products through their commercial network.

9Elan (Perrigo)
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Elan (now part of Perrigo) was an early commercial distribution partner for OEP, helping establish the company's credentials as a premier distributor for European pharmaceutical companies entering Asian markets.

oeppharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

11Plethora
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

oeppharma.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

15Kissei Pharmaceutical
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

oeppharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

17Tissuetech
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

oeppharma.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

China-based global CRO/CDMO with significantly larger scale than OEP; competes for CMO/CDMO contracts in injectable and oral dosage manufacturing from Asia.

TypeBroad incumbent
Description

French specialty pharma (dermo-cosmetics, oncology, CNS) — flagship OEP licensing partner of 40 years; comparable specialty pharma profile and shared Asia distribution economics.

TypeDirect peer
Description

Taiwan-based CDMO with FDA/EU GMP-certified facilities offering oral dose and injectable manufacturing plus specialty distribution — the closest comparable to OEP's integrated platform in scale and geography.

TypeDirect peer
Description

US specialty pharma using proprietary drug delivery platforms (ORADUR) — co-development partner with OEP for Methydur; directly comparable modified-release technology and licensing-out model.

TypeBroad incumbent
Description

Global CDMO with broad oral, injectable, and specialty delivery capabilities; competes with OEP for Western pharma CMO/CDMO contracts, though at much larger scale.

TypeBroad incumbent
Description

Italian specialty pharma (respiratory, rare disease) — OEP licensing partner for respiratory products in Asia; comparable European specialty pharma leveraging OEP-like regional distribution.

7Lotus Pharmaceutical
TypeDirect peer
Description

Taiwan-headquartered specialty generics company with strong Asian distribution and 505(b)(2)-style product development — overlaps OEP's Asian commercial platform and modified-release portfolio.

TypeDirect peer
Description

Taiwan-based API and injectable manufacturer with global CDMO services and ANDA generics; directly comparable to OEP's Taiwan manufacturing footprint and regulated-market generics pipeline.

TypeDirect peer
Description

Taiwan-based specialty pharma developing ophthalmic and oncology products with Asia-focused commercialization — comparable specialty-pharma strategy and Taiwan R&D/manufacturing base.

TypeDirect peer
Description

US CNS specialty pharma whose products (Trokendi XR, etc.) are licensed to OEP for Asia; similar modified-release CNS focus and partner-driven geographic expansion model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OEP Pharma

Pharmaceutical Manufacturingoeppharma.com

OEP Pharma is the US arm of Taiwan-listed OEP Group, a full-service pharmaceutical company providing Asia-Pacific licensing and distribution, US ANDA generic commercialization, 505(b)(2) co-development, and CMO/CDMO/CRO services to global pharma partners. It operates from two PIC/S-, EU GMP-, and US FDA-certified manufacturing facilities in Yunlin, Taiwan.

What OEP Pharma does

OEP Pharma is the US commercial identity of OEP Group, a publicly traded (TWSE), founder-led pharmaceutical company founded in 1982 in Taiwan by Peter Tsai. The company operates as a vertically integrated pharmaceutical platform with ~1,000 employees across 10 countries, combining (1) Asian licensing and distribution of branded pharmaceuticals via a 350+ person sales force in 7 countries (Taiwan, Hong Kong, Singapore, Malaysia, Vietnam, Indonesia, Myanmar), (2) ANDA generic products commercialized in the US through distribution partners such as PAI (e.g., Vancomycin hydrochloride capsules), (3) co-development of 505(b)(2) specialty products with partners including DURECT (Methydur / ORADUR-Methylphenidate ER) and in-licensing of late-stage assets from partners including CEL-SCI (Multikine cancer immunotherapy, 9 countries) and Supernus (Trokendi XR migraine, 7 Asian countries), and (4) CMO/CDMO and CRO/clinical-trial-operations services. Revenue is generated through licensing royalties and distribution margins on Asian branded sales, transaction-based US generic sales via channel partners, development fees and milestones from 505(b)(2) co-development, and managed-service CMO/CDMO/CRO contracts for global pharma customers.

The technical backbone is two PIC/S GMP, EU GMP, US FDA (oral-dosage) and Taiwan FDA-certified manufacturing facilities in Yunlin, Taiwan, totaling roughly 286,000 square feet (162,532 sq ft oral-dosage with 16 production suites, 30 cleanrooms, and 4 packaging lines; 123,318 sq ft injectables with fully integrated isolator for sterile fill-finish through lyophilization). Capability depth centers on complex modified-release oral solids — Multi-Phasic Release Technology (MPRT), Multi-Day Transdermal Drug Delivery (MTDD), Zero Order Release osmotic and pellet systems (OROS and PROS), and Nanoparticle Micellar Delivery — plus specialty injectables in liposomes, emulsions, suspensions, microspheres, and nanoparticles. TAA-compliance (Taiwan being a TAA-compliant country) permits direct US government sales.

The customer base is enterprise pharma: long-term Asian distribution partners (Pierre Fabre, Sanofi-Rhône-Poulenc, Chiesi, UCB, Elan/Perrigo, Teva, Kissei, Recordati) and Western co-development partners (DURECT, CEL-SCI, Supernus, Debiopharm, Plethora, Synthon, Summit Therapeutics, Tissuetech, Nanocarrier, Second Sight). The website discloses both market cap and revenue at $200MM. Strategic emphasis through 2019–2023 is North America (San Diego HQ established 2019, US FDA certification pursuit on the injectables plant) layered on top of the established Asian commercial franchise.

OEP Pharma firmographics

Firmographics
Name
OEP Pharma
Legal name
OEP Pharma
Website
https://oeppharma.com
Company type
Public
Founded year
1982
Operating status
Operating
Headcount range
1–10 employees
Short description
OEP Pharma is the US arm of Taiwan-listed OEP Group, a full-service pharmaceutical company providing Asia-Pacific licensing and distribution, US ANDA generic commercialization, 505(b)(2) co-development, and CMO/CDMO/CRO services to global pharma partners. It operates from two PIC/S-, EU GMP-, and US FDA-certified manufacturing facilities in Yunlin, Taiwan.
Ownership category
akta.pro rank

OEP Pharma industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Generic pharmaceutical manufacturing
  • Contract pharmaceutical manufacturing
  • Drug delivery technology
  • Pharmaceutical licensing distribution
  • Specialty pharma co-development

Where OEP Pharma is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices12 records

Markets served

OEP Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Licensing & Distribution of Branded Pharma in Asia: OEP serves as commercial partner for global pharmaceutical companies, distributing branded products through their extensive Asian sales networks. Revenue comes from licensing fees, distribution margins, and milestone payments.
  2. ANDA Products (Generic Pharmaceuticals): Manufacturing and marketing generic pharmaceutical products in the US and select markets through commercial distributors. Revenue from product sales through distribution partners.
  3. Co-development of 505(b)(2)s: Co-development of specialty pharmaceutical products with partners, providing financial resources, technology, and manufacturing capacity. Revenue from development fees, regulatory milestones, and product commercialization.
  4. CMO/CDMO/CRO Services: Contract manufacturing and development services for oral dosage and injectable products. Services include analytical method development, clinical trial management, quality control, and compendial testing.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

OEP Pharma product offering

Product offering

Core offering

OEP Pharma is a full-service global pharmaceutical company that develops, manufactures, and distributes drug products across North America and Asia-Pacific. Its operations span ANDA generic manufacturing, 505(b)(2) specialty co-development, branded pharmaceutical licensing and distribution in Asia through 350+ person sales teams, and CMO/CDMO/CRO services executed from two FDA-certified, PIC/S GMP-compliant facilities in Yunlin, Taiwan.

Product overview

OEP Pharma is a full-service pharmaceutical company offering a unified platform spanning drug development, manufacturing, and commercial distribution. Its product portfolio consists of three core pillars: (1) a growing ANDA portfolio of generic pharmaceuticals (immediate-release and controlled-release products including Vancomycin, Carisoprodol, Miglitol, Glyburide, Pitavastatin, Ezetimibe, Rivastigmine), all manufactured in TAA-compliant Taiwan; (2) a 505(b)(2) pipeline of specialty pharma products co-developed with partners such as DURECT (ORADUR-Methylphenidate ER / Methydur for ADHD) and in-licensed from companies such as CEL-SCI (Multikine, cancer immunotherapy) and Supernus Pharmaceuticals (Trokendi XR, CNS/migraine); and (3) CMO/CDMO and CRO services including oral dosage manufacturing (complex modified-release), cytotoxic injectables manufacturing, analytical services, clinical trial operations, and commercialization across Asia. These capabilities are interconnected: OEP manufactures its own portfolio while also offering manufacturing as a service to partners, and leverages its sales networks to distribute both self-manufactured and in-licensed products across North America and Asia-Pacific.

Differentiator

Problem solved

Functional benefit

Products and services

  • ANDA Generic Pharmaceutical Portfolio Out-licensed and distributed generic pharmaceuticals (ANDA products) for the US market via commercial distributors such as PAI, manufactured at OEP's FDA-certified facilities in Yunlin, Taiwan.
  • 505(b)(2) Specialty Pharmaceutical Pipeline Specialty pharmaceutical products developed via the 505(b)(2) regulatory pathway, co-developed with partners such as DURECT, with some marketed in Taiwan.
  • Vancomycin Hydrochloride Capsules An antibiotic generic medication marketed in the U.S. via out-licensing partner PAI (Pharmaceutical Associates, Inc.), part of OEP's ANDA portfolio.
  • ORADUR-Methylphenidate ER / Methydur A 505(b)(2) ADHD drug co-developed with DURECT using ORADUR technology; OEP holds development and commercialization rights in 14 Asian and South Pacific countries and it is approved and commercially launched in Taiwan.
  • Multikine CEL-SCI's lead investigational cancer immunotherapy drug, exclusively in-licensed by OEP for distribution in 9 countries.
  • Trokendi XR A CNS drug that helps prevent migraines, in-licensed from Supernus Pharmaceuticals and launched in 7 Asian countries.
  • Branded Asia Pharmaceutical Portfolio Branded pharmaceutical products marketed across Asian markets including Zulitor, Trokendi, Pitator, Navelbine, Methydur, and others covering cardiovascular, neurology, diabetes, respiratory, and oncology treatments.
  • Injectables Manufacturing (Cytotoxic Oncology) Contract manufacturing of cytotoxic injectable oncology products using fully integrated isolators for sterile production from filling to lyophilization, supporting liposomes, emulsions, suspensions, microspheres, and nanoparticles delivery platforms from a 123,318 square foot PIC/S GMP-certified facility in Yunlin, Taiwan.
  • Oral Dosage Manufacturing Contract manufacturing of complex modified-release oral dosage forms from a 162,532 square foot PIC/S GMP, EU GMP, Taiwan and US FDA-certified facility in Yunlin, Taiwan, with 16 production suites, 30 cleanrooms, and 4 packaging lines.
  • CMO/CDMO Services Integrated contract manufacturing and development services for oral dosage and injectable products, including analytical method development and validation, quality control, and compendial testing (USP, BP, EP, JP), from FDA-certified, PIC/S GMP facilities in Taiwan.
  • CRO / Clinical Trial Operations Services Agile clinical trial research services including site selection, trial management, and delivery of high-quality clinical data in Asia (Taiwan, Singapore, Korea), Australia, and New Zealand.
  • Licensing and Distribution Services (Branded Pharma in Asia) Commercial licensing and distribution of branded pharmaceutical products across Asia, leveraging nearly 40 years of local regulatory expertise and 350+ person sales teams in 7 countries.
  • 505(b)(2) Co-Development Services Co-development partnerships for 505(b)(2) specialty pharmaceutical products, providing financial resources, proprietary drug delivery technology, and manufacturing capacity to bring specialty pharmaceuticals to market.

Companies that use OEP Pharma

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

OEP Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

OEP Pharma partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core, flagship and minor.

  • DURECT CorporationcoreStrategic or Co-development Partner · 1 January 2009In 2009, DURECT granted OEP the development and commercialization rights to ORADUR-Methylphenidate ER Capsule (Methydur Sustained Released Capsules), its lead ORADUR-ADHD program, in 14 Asian and South Pacific countries. Together, OEP and DURECT developed a lead formulation based on clinical trial research. OEP oversaw phase III clinical trials in Taiwan, handles manufacturing, and has received or is pursuing regulatory approvals in 14 countries including Australia and New Zealand.
  • PAI (Pharmaceutical Associates, Inc.)coreChannel Partner/ Reseller/ DistributorOEP's ANDA portfolio provides high-quality generic medications at affordable prices. With commercial partner PAI, they launched Vancomycin hydrochloride capsules, a commonly used antibiotic, into the US market. PAI distributes the product through their North American distribution network.
  • CEL-SCI CorporationcoreStrategic or Co-development PartnerCEL-SCI is a pioneer in cancer immunotherapy drugs. OEP has an exclusive licensing agreement for Multikine, CEL-SCI's lead investigational therapy. OEP invested in CEL-SCI, funded a portion of Multikine's nine-year Phase III clinical trial, and obtained licensing rights to distribute Multikine in nine countries. The global Phase 3 study has ended and is in the data analysis stage. It is believed to be the largest head and neck cancer clinical study ever conducted.
  • Supernus PharmaceuticalscoreChannel Partner/ Reseller/ DistributorOEP partnered with Supernus Pharmaceuticals to launch Trokendi XR, a CNS drug that helps prevent migraines, in 7 Asian countries. OEP leverages their local sales teams and regulatory expertise to commercialize the product in the region.
  • Pierre FabreflagshipChannel Partner/ Reseller/ DistributorPierre Fabre is a long-standing commercial partner of OEP for branded pharmaceutical distribution in Asia. OEP has been the commercial partner of choice for Pierre Fabre for nearly 40 years, helping them access Asian markets including Taiwan and ASEAN countries.
  • Sanofi (Rhône-Poulenc)flagshipChannel Partner/ Reseller/ DistributorSanofi's Rhône-Poulenc division was one of OEP's early major commercial distribution partners, establishing the company's reputation as the regional distributor of choice in the 1980s and 1990s.
  • ChiesicoreChannel Partner/ Reseller/ DistributorChiesi partnered with OEP for licensing of respiratory products in Asian markets. OEP secured licensing deals to expand Chiesi's respiratory product portfolio into the Asian region through their established sales networks.
  • UCBcoreChannel Partner/ Reseller/ DistributorUCB partnered with OEP for licensing of their CNS portfolio in Asian markets. OEP led the expansion of sales into Asian markets for UCB's central nervous system products through their commercial network.
  • Elan (Perrigo)flagshipChannel Partner/ Reseller/ DistributorElan (now part of Perrigo) was an early commercial distribution partner for OEP, helping establish the company's credentials as a premier distributor for European pharmaceutical companies entering Asian markets.
  • DebiopharmminorStrategic or Co-development PartnerListed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.
  • PlethoraminorStrategic or Co-development PartnerListed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.
  • RecordatiminorChannel Partner/ Reseller/ DistributorListed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.
  • Second SightminorStrategic or Co-development PartnerListed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.
  • SYNTHONminorStrategic or Co-development PartnerListed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.
  • Kissei PharmaceuticalminorChannel Partner/ Reseller/ DistributorListed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.
  • Summit TherapeuticsminorStrategic or Co-development PartnerListed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.
  • TissuetechminorChannel Partner/ Reseller/ DistributorListed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.
  • Teva PharmaceuticalminorChannel Partner/ Reseller/ DistributorListed as a partner on the Partners and Results page, indicating a commercial or licensing relationship for pharmaceutical products.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

OEP Pharma competitors and assessment

Company assessment

Broad incumbents

  • WuXi AppTec: China-based global CRO/CDMO with significantly larger scale than OEP; competes for CMO/CDMO contracts in injectable and oral dosage manufacturing from Asia.
  • Pierre Fabre: French specialty pharma (dermo-cosmetics, oncology, CNS) — flagship OEP licensing partner of 40 years; comparable specialty pharma profile and shared Asia distribution economics.
  • Catalent: Global CDMO with broad oral, injectable, and specialty delivery capabilities; competes with OEP for Western pharma CMO/CDMO contracts, though at much larger scale.
  • Chiesi Farmaceutici: Italian specialty pharma (respiratory, rare disease) — OEP licensing partner for respiratory products in Asia; comparable European specialty pharma leveraging OEP-like regional distribution.

Direct peers

  • Bora Pharmaceuticals: Taiwan-based CDMO with FDA/EU GMP-certified facilities offering oral dose and injectable manufacturing plus specialty distribution — the closest comparable to OEP's integrated platform in scale and geography.
  • DURECT Corporation: US specialty pharma using proprietary drug delivery platforms (ORADUR) — co-development partner with OEP for Methydur; directly comparable modified-release technology and licensing-out model.
  • Lotus Pharmaceutical: Taiwan-headquartered specialty generics company with strong Asian distribution and 505(b)(2)-style product development — overlaps OEP's Asian commercial platform and modified-release portfolio.
  • ScinoPharm Taiwan: Taiwan-based API and injectable manufacturer with global CDMO services and ANDA generics; directly comparable to OEP's Taiwan manufacturing footprint and regulated-market generics pipeline.
  • Formosa Pharmaceuticals: Taiwan-based specialty pharma developing ophthalmic and oncology products with Asia-focused commercialization — comparable specialty-pharma strategy and Taiwan R&D/manufacturing base.
  • Supernus Pharmaceuticals: US CNS specialty pharma whose products (Trokendi XR, etc.) are licensed to OEP for Asia; similar modified-release CNS focus and partner-driven geographic expansion model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

OEP Pharma social profiles

Digital presence

OEP Pharma compliance and trust

Trust signal

Compliance9 records

OEP Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OEP Pharma leadership team

Management profile

Number of profiles

Profiles6 records

OEP Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

OEP Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OEP Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OEP Pharma

What does OEP Pharma do?

OEP Pharma is a full-service global pharmaceutical company that develops, manufactures, and distributes drug products across North America and Asia-Pacific. Its operations span ANDA generic manufacturing, 505(b)(2) specialty co-development, branded pharmaceutical licensing and distribution in Asia through 350+ person sales teams, and CMO/CDMO/CRO services executed from two FDA-certified, PIC/S GMP-compliant facilities in Yunlin, Taiwan.

Is OEP Pharma a public or private company?

OEP Pharma is a public company. It is classified as public and is currently operating.

When was OEP Pharma founded?

OEP Pharma was founded in 1982. It employs 1 to 10 people.

Where is OEP Pharma based?

OEP Pharma is headquartered in San Diego, United States, in the North America region.

How does OEP Pharma make money?

Four revenue lines are on record. Licensing & Distribution of Branded Pharma in Asia is the primary driver. The others are ANDA Products (Generic Pharmaceuticals), co-development of 505(b)(2)s and CMO/CDMO/CRO Services.

Who are OEP Pharma's main competitors?

Broad incumbents on record are WuXi AppTec, Pierre Fabre, Catalent and Chiesi Farmaceutici. Direct peers are Bora Pharmaceuticals, DURECT Corporation, Lotus Pharmaceutical, ScinoPharm Taiwan, Formosa Pharmaceuticals and Supernus Pharmaceuticals.

Does OEP Pharma have an API?

No public API is recorded for OEP Pharma.

What industry is OEP Pharma in?

OEP Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales